Results 161 to 170 of about 48,469 (263)

Follicular Lymphoma of the Rectum

Internal Medicine, 2008
Tanaka, Shouichi, Nagahara, Teruya, Hirakawa, Tomoko, Ohta, Takeyuki, Fujimoto, Tsuyoshi, Takada, Rie   +5 more
openaire   +3 more sources

Decoding IGLL5 Mutation‐Mediated BCR Signaling: A Novel Mechanism of CD8+ T Cell Exhaustion and Ocular MALT Lymphoma Progression

Advanced Science, Volume 13, Issue 44, 7 August 2026.
OAML harbors recurrent IGLL5 mutations that reinforce CD79A/CD79B‐associated BCR signaling. Mechanistic analysis of the S47G and A54G variants reveals induction of CXCL10/CXCL11, enhanced CD8+ T‐cell recruitment, and exhaustion‐associated dysfunction, supporting an immune‐tolerant niche.
Andi Zhao, Haoyu Wei, Chenyu Zhou, Xinping Sun, Shuyan Da, Haiyu Liu, Zijin Wang, Hui Zhu, Shiya Shen, Qing Shao, Qi Gong, Hu Liu, Xuejuan Chen   +12 more
wiley   +1 more source

BAL Flow Cytometry Unmasks Nodal T Follicular Helper Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis When Bone Marrow Is Nondiagnostic: A Case Report. [PDF]

Case Rep Pulmonol
Mwelwa MC.
europepmc   +1 more source

Post CAR‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

American Journal of Hematology, Volume 101, Issue 8, Page 1818-1827, August 2026.
ABSTRACT CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies.
Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen‐kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J. Frank   +12 more
wiley   +1 more source

Immunomorphological Analysis of the CD40-CD154 Interaction in T Follicular Helper Cell Lymphoma Emphasizes the Significance of the CD40-CD154 Axis in the Disease. [PDF]

Cells
Janotka DM, Borbényi Z, Piukovics K, Bukva M, Bakos A, Bagdi E, Krenács L.   +6 more
europepmc   +1 more source

Survival Outcomes and Prognostic Factors in Patients With Primary Central Nervous System Low‐Grade B‐Cell Lymphoma: A Population‐Based Cohort Study

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT The incidence of primary central nervous system low‐grade B‐cell lymphoma (PCNSL‐LG) is rare. We aimed to provide the first large‐scale analysis of treatment modalities, survival trends, and prognostic factors for PCNSL‐LG. Patient data diagnosed between 2000 and 2021 were extracted from the Surveillance, Epidemiology, and End Results (SEER ...
Lvwen Chen, Lei Cao, Yuxiao Zhao, Hailing Liu, Sanmei Wang, Miao Zhong, Xiran Wang, Jing Zhang, Xiaoyan Qu, Zhengxu Sun, Lei Fan, Ran Li   +11 more
wiley   +1 more source

Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma. [PDF]

Adv Ther
Boardman AP, Reguera Ortega JL, Wang P, Bar M, Kumar J, Farazi T, Martín García-Sancho A, Izutsu K.   +7 more
europepmc   +1 more source

Impact of Bone Marrow Involvement on the Success of Hematopoietic Stem Cell Mobilization in Patients With Lymphoma

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT The influence of bone marrow (BM) involvement at diagnosis on hematopoietic stem cell (HSC) mobilization outcomes remains to be fully elucidated, particularly in the contemporary plerixafor era. To address this issue, this multicenter retrospective cohort study including four lymphoma treatment centers evaluated patients who underwent their ...
Jie Lv, Zailin Yang, Xiaoqian Liu, Yao Liu, Weiping Liu, Jun Zhu, Ling Wang, Yuqin Song, Chen Zhang   +8 more
wiley   +1 more source

Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico. [PDF]

Antibodies (Basel)
Turco G, Tarantino D, Ferraro AG, Greco G, Tricarico D.   +4 more
europepmc   +1 more source

Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 440-451, August 2026.
The Coalition to Advance Real‐World Evidence through Randomized Controlled Trial Emulation (CARE) Initiative seeks to advance understanding of when real‐world data (RWD) can generate valid treatment effectiveness estimates by emulating completed oncology randomized controlled trials (RCTs).
Natalie Levy, Paige Sheridan, Ulka Campbell, David Lenis, Inish O'Doherty, Adina Estrin, Nileesa Gautam, Monica Iyer, Sarah McDonald, Andrew Belli, Gillis Carrigan, K. Arnold Chan, James Chen, Victoria Chia, Neil Dhopeshwarkar, Joy Eckert, Laura Fernandes, Joel Greshock, Rachele Hendricks‐Sturrup, Jenny Huang, XiaoLong Jiao, Sajan Khosla, Orsolya Lunacsek, Lynn McRoy, Yanina Natanzon, Osayi Ovbiosa, Nelson Pace, Simone Pinheiro, Megan Rees, Jennifer Rider, Mothaffar Fahed Rimawi, Travis Robinson, Carla Rodriguez‐Watson, Chithra Sangli, Khaled Sarsour, Sebastian Schneeweiss, Mark Shapiro, Mark Stewart, Aliki Taylor, C. K. Wang, Shirley Wang, Yiduo Zhang, Ann Madsen   +42 more
wiley   +1 more source